Bayesian refinement of a physiologically based pharmacokinetic model for ethylbenzene pharmacokinetics in mice, rats, and humans
Toxicological Sciences · 2025
DOI: 10.1093/toxsci/kfaf070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicological Sciences, 2025. Verfasst von Yu-Sheng Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Office of Research and Development, U.S. EPA, Washington, DC 20460, United States. Hauptthemen laut MEDLINE: Benzene Derivatives, Models, Biological. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural EPA.
Abstract (Originalsprache)
Although several physiologically based pharmacokinetic (PBPK) models exist for ethylbenzene (EB), a systematic evaluation of variability and uncertainty across species is still missing. This study aims to develop and validate a universal, population-based Bayesian PBPK model to study EB inhalation kinetics for mice, rats, and humans using a Markov Chain Monte Carlo (MCMC) approach to enhance model parameterization and its predictions. A comprehensive database was used for calibration and evaluation. This refined model demonstrates a superior or comparable fit to the data when contrasted with earlier published PBPK models for EB. Except for mouse fat and lung tissues, the concentrations of EB in tissues and its metabolites were generally within residual errors of 3-fold across species. Specifically, urinary concentrations of mandelic acid, the primary downstream metabolite of EB, are generally well predicted in both rats and humans. Our approach offers a better characterization of pharmacokinetic variability and uncertainty than previous EB models, with strong agreement between predictions and experimental data. This supports efforts to adopt PBPK modeling for data extrapolation from animal studies to inform human health assessments, thereby greatly promoting public health. The confidence in applying the current refined PBPK model could be increased by confirming the predictions made by our analysis with additional targeted data collection. Impact Statement: This study presents a refined Bayesian PBPK model that captures EB pharmacokinetics across species. It outperforms previous EB models and improves interspecies extrapolation for human health risk assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Office of Research and Development, U.S. EPA, Washington, DC 20460, United States.
- Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843, United States.
ORCID-Profile: Yu-Sheng Lin, Nan-Hung Hsieh, Paul M Schlosser, Michael W Dzierlenga, Hyunsu Ju
Förderung
- Intramural EPA
Zitieren
APA
Lin, Y. S., Hsieh, N. H., Schlosser, P. M., Dzierlenga, M. W., & Ju, H. (2025). Bayesian refinement of a physiologically based pharmacokinetic model for ethylbenzene pharmacokinetics in mice, rats, and humans. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfaf070
Vancouver
Lin YS, Hsieh NH, Schlosser PM, Dzierlenga MW, Ju H. Bayesian refinement of a physiologically based pharmacokinetic model for ethylbenzene pharmacokinetics in mice, rats, and humans. Toxicological Sciences. 2025. doi:10.1093/toxsci/kfaf070
BibTeX
@article{Lin2025,
author = {Lin, Yu-Sheng and Hsieh, Nan-Hung and Schlosser, Paul M and Dzierlenga, Michael W and Ju, Hyunsu},
title = {Bayesian refinement of a physiologically based pharmacokinetic model for ethylbenzene pharmacokinetics in mice, rats, and humans},
journal = {Toxicological Sciences},
year = {2025},
doi = {10.1093/toxsci/kfaf070}
}
EUVIMED